Ecabet sodium 可通过抑制活性氧的产生，促进幽门螺杆菌的根除，可用于胃肠道疾病的相关研究。

Ecabet sodium: a potential new agent in the management of distal colitis.

The inhibition profile of Cabozantinib against a broad panel of 270 human kinases is determined using luciferase-coupled chemiluminescence, 33P-phosphoryl transfer, or AlphaScreen technology. Recombinant human full-length, glutathione S-transferase tag, or histidine tag fusion proteins are used, and IC50 values are determined by measuring phosphorylation of peptide substrate poly(Glu, Tyr) at ATP concentrations at or below the Km for each respective kinase. The mechanism of kinase inhibition is evaluated using the AlphaScreen Assay by determining the IC50 values over a range of ATP concentrations[2].

86408-72-2

C20H27NaO5S

402.48

TA-2711;TA-2711E;伊卡倍特钠;Ecabet Sodium

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years